NEW YORK (
CHANGE IN RATINGS
was upgraded to buy at TheStreet Ratings.
was upgraded at Nomura to buy. $38 price target. Shareholder activism could help unlock value, Nomura said.
was upgraded at Wells Fargo to outperform from market perform. Company can deliver 15% annual earnings growth over the next several years, Wells Fargo said.
was initiated with an outperform rating at Oppenheimer. $300 price target. Eylea should continue to grow and the company is expanding into DME, Oppenheimer said.
was downgraded at Leerink Swann to market perform from outperform. $26 price target. Valuation call, as the company trades at a sizable premium to its peers, Leerink Swann said.
was initiated with a buy rating at Keybanc. $100 price target. Company has a strong growth profile, including exposure to Latin America, Keybanc said.
was downgraded to hold at TheStreet Ratings.
was initiated with a hold rating at Stifel Nicolaus. Valuation call, as the company still has little evidence of customer retention or success at lower price points, Stifel Nicolaus said.
was initiated with an outperform rating at Oppenheimer. $105 price target. Cystic Fibrosis treatments can continue to drive growth, Oppenheimer said.
was initiated with a hold rating at Benchmark. $2.98 price target. New management needs to show stabilized Web trends and material mobile acceleration, Benchmark said.
Stock Comments / EPS Changes
numbers were cut at BMO Capital. Estimates were reduced through 2014. Management cut guidance, BMO Capital said. Market Perform rating and new $15 price target.
numbers were increased at UBS. Estimates were boosted through 2015. Domestic business is positioned well, ahead of the holidays, UBS said. Neutral rating and new $35 price target.
numbers were reduced at BMO Capital. Shares are now seen reaching $27. Estimates were also cut, given lower operating growth, especially in the enterprise segment, BMO Capital said. Market Perform rating.
estimates, price target were boosted at Bank of America/Merrill Lynch. Shares are now seen reaching $90. Estimates were also increased, given higher HiSeq growth and lower expected operating costs, BofA/Merrill said. Buy rating.
estimates, price target were raised at BMO Capital. Shares are now seen reaching $50. Estimates were also increased, given the company's new guidance, BMO Capital said. Market Perform rating.
Read: 5 Vehicles Parents Want When They Can't Stand the Minivan
numbers were increased at Jefferies. Estimates were increased through 2014. Company is seeing higher volume growth, in response to price cuts, Jefferies said. Hold rating and new $101 price target.
estimates, price target were reduced at Jefferies. Shares are now seen reaching $14. Estimates were also cut, as the company is seeing slower demand across the board, Jefferies said. Hold rating.
estimates, price target were cut at UBS. Shares are now seen reaching $66. Estimates were also reduced, given the company's new guidance, UBS said. Neutral rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.